We are analyzing https://link.springer.com/article/10.1007/s10549-011-1364-y.

Title:
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy | Breast Cancer Research and Treatment
Description:
Modulation of estrogen signaling is one of the most successful modalities for the treatment of estrogen receptor (ER)-positive breast cancer, yet de novo and acquired resistance are frequent. Recent data suggests that the induction of autophagy may play a considerable role in promoting tumor cell survival and resistance to anti-estrogen therapy. Hence, bypassing autophagy may offer a novel strategy to enhance the anti-tumor efficacy of anti-estrogens. Histone deacetylases (HDAC) are involved in the regulation of steroid hormone receptor mediated cell signaling and their inhibition potentiates the anti-tumor effects of anti-estrogens. However, the mechanism underlying this anti-tumor activity is poorly understood. In this report, we show that the addition of an HDAC inhibitor redirects the response of ER-positive breast cancer cells when treated with tamoxifen from growth arrest to apoptotic cell death. This redirection requires functional ER signaling and is mediated by a depletion of Bcl-2 and an induction of Bax and Bak, manifesting in cytochrome C release and PARP cleavage. With combined treatment, a subpopulation of cells is refractory to apoptosis and exhibit a strong induction of autophagy. Inhibition of autophagy in these cells, using siRNA directed against Beclin-1 or treatment with chloroquine, further promotes the induction of apoptosis. Thus, supporting prior reports that autophagy acts as a survival mechanism, our findings demonstrate that HDAC and autophagy inhibition directs autophagy-protected cells into apoptotic cell death, which may impair development of tamoxifen resistance.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

article, cancer, pubmed, google, scholar, cas, breast, cells, autophagy, histone, deacetylase, cell, apoptosis, hdac, inhibition, death, treatment, inhibitor, estrogen, receptor, res, induction, resistance, human, expression, research, tamoxifen, access, privacy, cookies, content, antiestrogen, therapy, treat, clin, data, publish, search, thomas, signaling, role, tumor, antiestrogens, mechanism, refractory, oncol, lymphoma, information, log, journal,

Topics {✒️}

month download article/chapter cutaneous t-cell lymphoma 4-hydroxytamoxifen-induced cell death blocks tamoxifen-induced proliferation breast cancer cells estrogen receptor alpha positive breast cancer human breast cancer hdac inhibitor redirects functional estrogen receptor suberoylanilide hydroxamic acid anti-estrogen therapy therapeutic drug group histone deacetylase enhances human breast dcis full article pdf phase ii trial histone deacetylase inhibition human gastric cancer malignant glioma cells tumor suppressor mechanism privacy choices/manage cookies tamoxifen-induced killing related subjects histone h4 acetylation apoptotic cell death myc-induced model anti-tumor efficacy anti-tumor effects enhances mitochondrial depolarization anti-estrogens tamoxifen 10 μm 4oh-tamoxifen anti-proliferative action estrogen receptor anti-tumor activity estrogen signaling article thomas lung cancer patients check access instant access european economic area supporting prior reports mitochondrial membrane permeabilization double-edged sword electronic supplementary material dye exclusion assay histone deacetylase 1 histone deacetylase 2 histone deacetylase-1 recent data suggests

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
         description:Modulation of estrogen signaling is one of the most successful modalities for the treatment of estrogen receptor (ER)-positive breast cancer, yet de novo and acquired resistance are frequent. Recent data suggests that the induction of autophagy may play a considerable role in promoting tumor cell survival and resistance to anti-estrogen therapy. Hence, bypassing autophagy may offer a novel strategy to enhance the anti-tumor efficacy of anti-estrogens. Histone deacetylases (HDAC) are involved in the regulation of steroid hormone receptor mediated cell signaling and their inhibition potentiates the anti-tumor effects of anti-estrogens. However, the mechanism underlying this anti-tumor activity is poorly understood. In this report, we show that the addition of an HDAC inhibitor redirects the response of ER-positive breast cancer cells when treated with tamoxifen from growth arrest to apoptotic cell death. This redirection requires functional ER signaling and is mediated by a depletion of Bcl-2 and an induction of Bax and Bak, manifesting in cytochrome C release and PARP cleavage. With combined treatment, a subpopulation of cells is refractory to apoptosis and exhibit a strong induction of autophagy. Inhibition of autophagy in these cells, using siRNA directed against Beclin-1 or treatment with chloroquine, further promotes the induction of apoptosis. Thus, supporting prior reports that autophagy acts as a survival mechanism, our findings demonstrate that HDAC and autophagy inhibition directs autophagy-protected cells into apoptotic cell death, which may impair development of tamoxifen resistance.
         datePublished:2011-02-05T00:00:00Z
         dateModified:2011-02-05T00:00:00Z
         pageStart:437
         pageEnd:447
         sameAs:https://doi.org/10.1007/s10549-011-1364-y
         keywords:
            Breast cancer
            Histone deacetylase
            Anti-estrogen therapy
            Estrogen receptor
            Autophagy
            Apoptosis
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig6_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:130
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Scott Thomas
               affiliation:
                     name:University of California
                     address:
                        name:Division of Hematology and Oncology, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kenneth T. Thurn
               affiliation:
                     name:University of California
                     address:
                        name:Division of Hematology and Oncology, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elona Biçaku
               affiliation:
                     name:H. Lee Moffitt Cancer Center and Research Institute
                     address:
                        name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas C. Marchion
               affiliation:
                     name:H. Lee Moffitt Cancer Center and Research Institute
                     address:
                        name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pamela N. Münster
               affiliation:
                     name:University of California
                     address:
                        name:Division of Hematology and Oncology, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
      description:Modulation of estrogen signaling is one of the most successful modalities for the treatment of estrogen receptor (ER)-positive breast cancer, yet de novo and acquired resistance are frequent. Recent data suggests that the induction of autophagy may play a considerable role in promoting tumor cell survival and resistance to anti-estrogen therapy. Hence, bypassing autophagy may offer a novel strategy to enhance the anti-tumor efficacy of anti-estrogens. Histone deacetylases (HDAC) are involved in the regulation of steroid hormone receptor mediated cell signaling and their inhibition potentiates the anti-tumor effects of anti-estrogens. However, the mechanism underlying this anti-tumor activity is poorly understood. In this report, we show that the addition of an HDAC inhibitor redirects the response of ER-positive breast cancer cells when treated with tamoxifen from growth arrest to apoptotic cell death. This redirection requires functional ER signaling and is mediated by a depletion of Bcl-2 and an induction of Bax and Bak, manifesting in cytochrome C release and PARP cleavage. With combined treatment, a subpopulation of cells is refractory to apoptosis and exhibit a strong induction of autophagy. Inhibition of autophagy in these cells, using siRNA directed against Beclin-1 or treatment with chloroquine, further promotes the induction of apoptosis. Thus, supporting prior reports that autophagy acts as a survival mechanism, our findings demonstrate that HDAC and autophagy inhibition directs autophagy-protected cells into apoptotic cell death, which may impair development of tamoxifen resistance.
      datePublished:2011-02-05T00:00:00Z
      dateModified:2011-02-05T00:00:00Z
      pageStart:437
      pageEnd:447
      sameAs:https://doi.org/10.1007/s10549-011-1364-y
      keywords:
         Breast cancer
         Histone deacetylase
         Anti-estrogen therapy
         Estrogen receptor
         Autophagy
         Apoptosis
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1364-y/MediaObjects/10549_2011_1364_Fig6_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:130
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Scott Thomas
            affiliation:
                  name:University of California
                  address:
                     name:Division of Hematology and Oncology, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kenneth T. Thurn
            affiliation:
                  name:University of California
                  address:
                     name:Division of Hematology and Oncology, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elona Biçaku
            affiliation:
                  name:H. Lee Moffitt Cancer Center and Research Institute
                  address:
                     name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas C. Marchion
            affiliation:
                  name:H. Lee Moffitt Cancer Center and Research Institute
                  address:
                     name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pamela N. Münster
            affiliation:
                  name:University of California
                  address:
                     name:Division of Hematology and Oncology, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:130
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of California
      address:
         name:Division of Hematology and Oncology, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Hematology and Oncology, University of California, San Francisco, USA
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center and Research Institute
      address:
         name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center and Research Institute
      address:
         name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
         type:PostalAddress
      name:University of California
      address:
         name:Division of Hematology and Oncology, University of California, San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Scott Thomas
      affiliation:
            name:University of California
            address:
               name:Division of Hematology and Oncology, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Kenneth T. Thurn
      affiliation:
            name:University of California
            address:
               name:Division of Hematology and Oncology, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Elona Biçaku
      affiliation:
            name:H. Lee Moffitt Cancer Center and Research Institute
            address:
               name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Douglas C. Marchion
      affiliation:
            name:H. Lee Moffitt Cancer Center and Research Institute
            address:
               name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Pamela N. Münster
      affiliation:
            name:University of California
            address:
               name:Division of Hematology and Oncology, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Hematology and Oncology, University of California, San Francisco, USA
      name:Division of Hematology and Oncology, University of California, San Francisco, USA
      name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
      name:H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
      name:Division of Hematology and Oncology, University of California, San Francisco, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(138)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.4s.

LINK . SPRINGER . COM {}